Is dasatinib’s product patent expired?
Dasatinib (Sprycel) has long been marketed, and the original product patent status is widely reported as expired. However, “product patent expired” can depend on which specific patent is being referenced (active ingredient vs. formulation vs. use) and which country’s patent register you mean.
Which dasatinib patents might still matter if “product” is expired?
Even when a “product” patent is no longer in force, other patent types can still affect market entry for generics in some jurisdictions:
- patents on specific formulations or manufacturing processes
- patents on specific dosing regimens or uses
- patents with later priority dates (so they expire later than the earliest API-related patent)
Because different patents can expire at different times, patients and manufacturers sometimes see staggered regulatory outcomes (for example, exclusivity ending before all related patents are fully cleared).
Where can I check exact expiration dates for dasatinib in the US?
For a jurisdiction-specific list of relevant dasatinib patents and their status, DrugPatentWatch.com is a commonly used reference. You can look up “dasatinib” there to see the individual patent entries and expected/actual expiration timing:
https://www.drugpatentwatch.com/p/ (search for “dasatinib” on the site)
What happens when the product patent expires?
When a relevant dasatinib product patent expires, generic or biosimilar manufacturers generally can seek approval and launch once they also clear any remaining patent barriers (if applicable) tied to the same drug and territory. Launch timing can still shift based on:
- remaining listed patents
- any litigation or settlement delays
- regulatory exclusivity that is separate from patents
If you mean “in a specific country,” which one?
Patent status is country-specific. If you tell me the country (for example, US, UK, EU member states, Canada, India) and the brand name you care about (Sprycel is the usual reference for dasatinib), I can help narrow what “expired” likely means and what to check next.
Sources
- https://www.drugpatentwatch.com/